Stock CRXT CLARUS THERAPEUTICS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Clarus Therapeutics Holdings, Inc.

Equities

CRXT

US18271L1070

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CLARUS THERAPEUTICS HOLDINGS, INC. : Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Other Events (form 8-K)
AQ
Clarus Therapeutics Holdings, Inc. Went Out of Business
CI
CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
First Amended Combined Liquidation Plan and Disclosure Statement Approved for Clarus Therapeutics Holdings, Inc.
CI
CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
First Motion for Exclusivity Period Extension Approved For Clarus Therapeutics Holdings, Inc.
CI
First Motion for Exclusivity Period Extension Filed by Clarus Therapeutics Holdings, Inc.
CI
CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
First Amended Combined Liquidation Plan and Disclosure Statement Approved on Interim Basis for Clarus Therapeutics Holdings, Inc.
CI
First Amended Combined Liquidation Plan and Disclosure Statement Filed by Clarus Therapeutics Holdings, Inc.
CI
Combined Liquidation Plan and Disclosure Statement Filed by Clarus Therapeutics Holdings, Inc.
CI
CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
CLARUS THERAPEUTICS HOLDINGS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Clarus Therapeutics Holdings, Inc. Announces Termination of Robert Dudley as Chief Executive Officer
CI
Clarus Therapeutics Holdings, Inc. Announces Termination of Steven Bourne as Chief Financial Officer, Effective November 14, 2022
CI
Clarus Therapeutics Holdings, Inc. Announces Executive Changes
CI
Motion for Asset Sale Approved for Clarus Therapeutics Holdings, Inc.
CI
CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
CLARUS THERAPEUTICS HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRXT Stock
  4. News Clarus Therapeutics Holdings, Inc.